We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+13.82%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.4B
AUM Growth
+$48.4M
Cap. Flow
+$26.9M
Cap. Flow %
1.92%
Top 10 Hldgs %
65.74%
Holding
68
New
19
Increased
7
Reduced
4
Closed
19

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$122M
2
NRIX icon
Nurix Therapeutics
NRIX
+$30M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.6M
4
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$14M
5
KLRS
Kalaris Therapeutics
KLRS
+$13.3M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$69.1M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$40.6M
3
FATE icon
Fate Therapeutics
FATE
+$21.3M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$20.5M
5
DNLI icon
Denali Therapeutics
DNLI
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
26
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.52M 0.46%
+741,290
New +$6.78M
ITOS
27
DELISTED
iTeos Therapeutics
ITOS
$6.41M 0.46%
+260,000
New +$6.99M
DFHTU
28
DELISTED
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
$5.32M 0.38%
+500,000
New +$5.27M
PANA.U
29
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$4.68M 0.33%
+390,000
New +$4.49M
IRWD icon
30
CALL
Ironwood Pharmaceuticals
IRWD
$626M
$4.5M 0.32%
500,000
– –
OBIO icon
31
Orchestra BioMed
OBIO
$231M
$4.4M 0.31%
+400,000
New +$4.49M
DYN icon
32
Dyne Therapeutics
DYN
$4.28B
$4.34M 0.31%
+215,000
New +$4.72M
ACRS icon
33
Aclaris Therapeutics
ACRS
$744M
$3.94M 0.28%
1,531,312
– –
FSDC
34
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$3.92M 0.28%
+350,000
New +$3.75M
MTCR
35
DELISTED
Metacrine, Inc. Common Stock
MTCR
$3.4M 0.24%
+333,332
New +$3.41M
KYMR icon
36
Kymera Therapeutics
KYMR
$8.73B
$3.23M 0.23%
+100,000
New +$3.05M
CBIO
37
CALL
Crescent Biopharma
CBIO
$608M
$2.61M 0.19%
+8,500
New +$3.25M
RPRX icon
38
Royalty Pharma
RPRX
$26.6B
$2.1M 0.15%
50,000
– –
FPRX
39
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.79M 0.13%
379,945
– –
XCUR icon
40
Exicure
XCUR
$11.1M
$1.78M 0.13%
6,785
-4,370
-39% -$1.43M
PMVP icon
41
PMV Pharmaceuticals
PMVP
$58.7M
$1.77M 0.13%
+50,000
New +$1.84M
RPTX
42
DELISTED
Repare Therapeutics
RPTX
$1.54M 0.11%
50,000
– –
MGTX icon
43
MeiraGTx Holdings
MGTX
$1.09B
$1.25M 0.09%
94,819
– –
ICPT
44
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.05M 0.07%
25,300
– –
UBX
45
DELISTED
Unity Biotechnology
UBX
$1.02M 0.07%
+29,600
New +$1.87M
XOMA
46
DELISTED
Xoma
XOMA
$957K 0.07%
50,809
– –
ASMB icon
47
CALL
Assembly Biosciences
ASMB
$507M
$293K 0.02%
+1,483
New +$373K
SVRA icon
48
Savara
SVRA
$1.09B
$62K ﹤0.01%
56,500
-1,376,164
-96% -$2.35M
ACAD icon
49
Acadia Pharmaceuticals
ACAD
$4.45B
– –
-135,413
Closed -$6.56M
CRNX icon
50
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-859,802
Closed -$15.1M
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2020 Portfolio in Review

As of Q3 2020, EcoR1 Capital held 68 positions worth $1.4B, up 3.6% from $1.35B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

EcoR1 Capital's Q3 2020 filing shows 19 new, 7 increased, 4 reduced and 19 closed positions. Its largest new stake was Relay Therapeutics: 3,200,649 shares worth $136M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $69.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier.

  • EcoR1 Capital's largest Q3 2020 buy was Relay Therapeutics: 3,200,649 shares worth $136M.
  • EcoR1 Capital added most to Mirati Therapeutics, Inc. Common Stock in Q3 2020, an estimated $14.6M increase.
  • EcoR1 Capital's biggest Q3 2020 reduction was Assembly Biosciences, cutting an estimated $12.7M.
  • EcoR1 Capital fully exited Dicerna Pharmaceuticals, Inc. in Q3 2020, selling an estimated $69.1M.
  • EcoR1 Capital's ten largest holdings make up 66% of its $1.4B portfolio in Q3 2020.
  • EcoR1 Capital opened 19 new positions and closed 19 in Q3 2020.
  • EcoR1 Capital's portfolio value rose 3.6% quarter-over-quarter to $1.4B.

Based on EcoR1 Capital's 13F filing for Q3 2020, filed 16 Nov 2020.